Syntekabio-JW JoongWae Pharmaceutical, MOU for Joint Research on Innovative Drug Development Using AI

[Asia Economy Reporter Hyunseok Yoo] AI-based new drug development company Syntekabio announced on the 19th that it has signed a memorandum of understanding (MOU) for mutual cooperation with JW Pharmaceutical to conduct joint research on new drug development using artificial intelligence (AI).

With this MOU signing as an opportunity, JW Pharmaceutical and Syntekabio have decided to jointly begin research on new drug candidate substances targeting disease-causing proteins. They also agreed to maintain a continuous cooperative relationship to discover research and development projects for treatments with high unmet needs and to accelerate new drug development research using AI.

Jongseon Jeong, CEO of Syntekabio, said, “We are very pleased to strengthen our friendly cooperative relationship with JW Pharmaceutical and to expand the scope of cooperation by starting joint research on new drug development targeting specific target proteins using our DeepMatcher® solution. We will actively strive to achieve innovative results in the AI-based new drug development field through close cooperation between the two companies.”

Sungyeol Lee, CEO of JW Pharmaceutical, said, “With the advancement of basic science, new protein pathways and their correlations with diseases have been identified, intensifying the competition to pioneer new drug development targeting these pathways. Based on Syntekabio’s big data and AI-based technology, we will accelerate the development of patient-customized new drugs with novel mechanisms of action.”

Meanwhile, DeepMatcher is an AI platform for discovering synthetic new drug candidates independently developed by Syntekabio. It simulates the three-dimensional binding structure according to actual physical environmental changes when target proteins and drugs bind, predicting whether binding occurs. It is characterized by rapid screening capabilities through its own supercomputing infrastructure.

This content was produced with the assistance of AI translation services.